LncRNA CTB-31O20.2 promotes the progression of hepatocellular carcinoma by targeting the miR-139-5p/ROCK1 axis
Archives of Biochemistry and Biophysics · 2025
DOI: 10.1016/j.abb.2025.110619 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Biochemistry and Biophysics, 2025. Verfasst von Dizhong Ye und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid and Breast Surgery, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, China. Hauptthemen laut MEDLINE: MicroRNAs, rho-Associated Kinases, Carcinoma, Hepatocellular, RNA, Long Noncoding. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Natural Science Foundation of Fujian Province, Fujian Medical University.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a primary cause of mortality from cancer, necessitating novel insights into its molecular underpinnings. Recent evidence points to the significant roles of lncRNAs in HCC progression, among which CTB-31O20.2 has emerged as a potentially crucial player. This study utilized RNA sequencing to identify differentially expressed lncRNAs in HCC tissues, focusing on CTB-31O20.2. We employed RT-qPCR, Western blotting, and dual-luciferase reporter assays to evaluate the expression patterns of CTB-31O20.2 in HCC cells and its interactions with miR-139-5p and Rho-associated coiled-coil containing protein kinase1 (ROCK1). In vivo effects were analyzed using a xenograft mouse model. CTB-31O20.2 was significantly upregulated in HCC tissues and cell lines. Silencing CTB-31O20.2 in Hep3B and HepG2 cells reduced malignancy, evidenced by decreased viability, colony formation, and invasion, and increased apoptosis. These cellular behaviors were associated with alterations in apoptosis-related proteins and epithelial-mesenchymal transition (EMT) markers. CTB-31O20.2 was shown to interact with miR-139-5p, and its silencing upregulated miR-139-5p, leading to reduced ROCK1 expression. Conversely, miR-139-5p inhibition reversed the anti-tumor effects of CTB-31O20.2 silencing. Overexpression of ROCK1 negated the inhibitory effects on HCC cell malignancy induced by CTB-31O20.2 depletion. In vivo, CTB-31O20.2 silencing significantly reduced tumor growth in a xenograft model. Our findings reveal that CTB-31O20.2 contributes to HCC progression by modulating miR-139-5p and ROCK1 expression. These results highlight CTB-31O20.2 as a potential therapeutic target in HCC, providing a new perspective on the mechanisms driving HCC pathogenesis and progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thyroid and Breast Surgery, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, China.
- Department of Thyroid and Breast Surgery, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, China. Electronic address: quanguangqian_ye@sina.com.
Förderung
- Natural Science Foundation of Fujian Province
- Fujian Medical University
Zitieren
APA
Ye, D., Chen, B., Wang, X., Chen, W., Ye, F., & Quan, G. (2025). LncRNA CTB-31O20.2 promotes the progression of hepatocellular carcinoma by targeting the miR-139-5p/ROCK1 axis. Archives of Biochemistry and Biophysics. https://doi.org/10.1016/j.abb.2025.110619
Vancouver
Ye D, Chen B, Wang X, Chen W, Ye F, Quan G. LncRNA CTB-31O20.2 promotes the progression of hepatocellular carcinoma by targeting the miR-139-5p/ROCK1 axis. Archives of Biochemistry and Biophysics. 2025. doi:10.1016/j.abb.2025.110619
BibTeX
@article{Ye2025,
author = {Ye, Dizhong and Chen, Biyan and Wang, Xiangfa and Chen, Weiwei and Ye, Feng and Quan, Guangqian},
title = {LncRNA CTB-31O20.2 promotes the progression of hepatocellular carcinoma by targeting the miR-139-5p/ROCK1 axis},
journal = {Archives of Biochemistry and Biophysics},
year = {2025},
doi = {10.1016/j.abb.2025.110619}
}
EUVIMED